Therapeutic vaccine against non-Hodgkin's lymphoma targeting the immune adjuvant properties of Natural Killer T cells.

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1044355

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Patients with lymphoma cancers initially respond well to treatment, but later relapse with disease. The immune system can be effective at controlling cancer. A potential treatment option is to boost the natural immune response against cancer. This study investigates a vaccine that activates a certain immune cell, NKT cells, to fight lymphomas by delivering an NKT cell-activating molecule. Outcomes will allow assessment of combining an NKT-based vaccine with established treatments for lymphoma.

Funded Activity Details

Start Date: 01-01-2013

End Date: 01-01-2016

Funding Scheme: Project Grants

Funding Amount: $451,606.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Tumour Immunology

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

cancer immunotherapy | cellular immunology | immune regulation | innate immunity | tumour immunity

Related Links